Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Bourg En Bresse – page 6

85 clinical trials in Bourg En Bresse, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bourg En Bresse at a glance
85
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

85 trials in Bourg En Bresse

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Unicancer

Nephrotic syndrome

Not recruiting

Study of Rituximab, Prednisolone and Betamethasone in Adult Patients with First Episode of Minimal Change Nephrotic Syndrome to Prevent Disease Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer+1

Not recruiting

Study Comparing Chemotherapy and Abemaciclib with Hormone Therapy for Patients with ER+ HER2- Metastatic Breast Cancer with Visceral Involvement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Study of Encorafenib and Binimetinib for Patients with BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Sepsis

Not recruiting

Study of hydrocortisone and fludrocortisone combination versus placebo in adults with sepsis in intensive care unit to determine corticosteroid response

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Francois Baclesse

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Bourg En Bresse

What the registry says about research in the country

01 Oncology - Multiple Myeloma

Innovative research examining multiple myeloma treatments, including studies of elranatamab-lenalidomide combinations and evaluation of daratumumab therapies. Investigations focus on optimizing treatment duration and improving patient outcomes.

  • Treatment optimization studies
  • Therapy duration assessment
  • Novel drug combinations

Several trials are exploring personalized approaches for both newly diagnosed and relapsed cases.

02 Breast Cancer Research

Comprehensive studies focusing on breast cancer treatments, particularly in HER2-negative and hormone-receptor-positive cases. Research includes innovative approaches to hormone therapy and targeted treatments.

  • Metastatic breast cancer therapies
  • Hormone therapy optimization
  • Treatment de-escalation strategies

Trials aim to personalize treatment approaches and improve long-term outcomes.

03 Critical Care Medicine

Important studies in intensive care focusing on respiratory support and sepsis management. Research includes evaluation of high-flow nasal oxygen therapy protocols and corticosteroid treatments.

  • Respiratory support optimization
  • Sepsis treatment protocols
  • Patient weaning strategies

These trials aim to improve critical care outcomes and standardize treatment approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.